The study also suggests that any reduction in payments associated with proposed cuts to the Children Health Insurance Program (CHIP), which operates in tandem with Medicaid in most states, could mean less access to care, said Brendan Saloner, a researcher at the Johns Hopkins Berman Institute of Bioethics and Bloomberg School of Public Health

Quick Read

The Trump administration wants to make a major change to Medicaid, but there’s not a lot of evidence for one of its key assertions

Quick Read

Pfizer, one of the world’s largest drug companies, announced over the weekend that it would stop work on new drugs to fight Alzheimer’s disease and Parkinson’s disease. The reason? Pfizer believes that research on the two diseases doesn’t make sense financially

Quick Read

But with plans to ease cost concerns. The first gene therapy in the U.S., approved last month to treat a rare, inherited form of blindness, now has a price tag: $850,000

Quick Read

Gale Dunham, a pharmacist in Calistoga, Calif., knows the devastation the opioid epidemic has wrought, and she is glad the anti-overdose drug naloxone is becoming more accessible. But so far, Dunham said, she has not taken advantage of a California law that allows pharmacists to dispense the medication to patients without a doctor’s prescription

Quick Read

Renda Bower knows well the cost of drugs to treat rheumatoid arthritis – her husband, son and daughter all have the painful, disabling autoimmune disease. And the family’s finances revolve around paying for them

Quick Read

When the government says a new drug is approved for sale, the first thing many companies do is announce what it will cost. Not Spark Therapeutics, though

Quick Read

Facing bipartisan hostility over high drug prices in an election year, the pharma industry’s biggest trade group boosted revenue by nearly a fourth last year and spread the millions collected among hundreds of lobbyists, politicians and patient groups, new filings show

Quick Read